ArticleClinical and translational allergy2026
Longitudinal Proteomic Signatures of Dupilumab and Tralokinumab Treated Atopic Dermatitis Patients.
Article in Clinical and translational allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundAtopic dermatitis (AD) is a chronic inflammatory disease driven by Type 2 (Th2) inflammation. Dupilumab (anti-IL-4Rα) and tralokinumab (anti-IL-13) are effective biologic therapies, but a direct comparison of their longitudinal effects on the systemic proteome is lacking. This exploratory study aimed to identify and to differentially analyze the proteomic signatures in AD patients treated with dupilumab versus tralokinumab.
methodsIn this prospective, observational study, serum samples were collected from patients with moderate-to-severe AD at baseline and after 12 months of treatment with either dupilumab (n = 10) or tralokinumab (n = 10). A cohort of healthy controls (n = 12) was included for baseline comparison. Proteomic profiling was performed using a targeted 440-protein array, and data were analyzed for differential expression and pathway enrichment.
resultsAt baseline, AD patients exhibited a distinct proteomic signature compared to healthy controls, characterized by a strong Th2 inflammatory profile and enrichment of the IL-4/IL-13 signaling pathway. After 12 months, both therapies reduced the core Th2 inflammatory signature with downregulation of key markers like CCL17. Dupilumab induced a broader immunomodulation, showing a more pronounced upregulation of Th1 associated proteins compared to tralokinumab. Furthermore, the therapies had opposing effects on tissue repair and metabolic proteins; dupilumab treatment led to a decrease in TNFSF11 and Sclerostin (SOST), while these were increased after tralokinumab treatment.
conclusionDupilumab and tralokinumab effectively target the Th2 axis in AD but their longitudinal systemic immune modulation differs in respect to Th1-Th17 and tissue repair markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.